MedTrace Logo

Safety Study of a Cell Penetrating Peptide (p28) to Treat Solid Tumors That Resist Standard Methods of Treatment

NCT00914914 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 15

Last updated 2014-10-28

No results posted yet for this study

Summary

The purpose of this study is to evaluate the safety of an experimental drug (p28) as a treatment for certain advanced cancers which express a protein called p53 and which have not responded to prior treatment.

Conditions

  • Refractory Solid Tumors

Interventions

DRUG

p28

p28 will be dissolved in normal saline and infused intravenously into the patient over 15-30 minutes.

Sponsors & Collaborators

  • Dr. Tapas K. Das Gupta

    lead INDUSTRY

Principal Investigators

  • Michael A Warso, M.D. · University of Illinois Department of Surgical Oncology

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2009-04-30
Primary Completion
2011-04-30
Completion
2011-06-30

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00914914 on ClinicalTrials.gov